Forbion Co-Leads $20M Series A in PACT to Scale Revolutionary Biomaterials
- $20 million Series A co-led by Forbion BioEconomy and HV Capital
- PACT’s biomaterial offers a scalable and sustainable alternative to traditional textile coatings such as plastic with unique aesthetics and handfeel
- Funding supports commercialization with several global brands and the scale-up of production
Naarden, The Netherlands – 30 October, 2025 – Forbion, a leading global life sciences venture capital firm with deep roots in Europe, today announced it has co-led a $20 million Series A financing in PACT, a biomaterials innovator redefining how consumer goods are made. The round was co-led by Forbion’s BioEconomy Fund I and HV Capital, with participation from existing investors.
PACT’s flagship product, Oval, is a next-generation collagen-based biomaterial designed for roll-to-roll manufacturing. Oval is engineered to meet the creative, commercial, and environmental demands of global brands, offering a drop-in solution to replace plastic across fashion, interiors, footwear, and automotive applications.
The funding will accelerate Oval’s commercial rollout and support the scale-up of production capacity at PACT’s newly commissioned pilot line in Cambridge. This expansion comes as brands face mounting pressure from new EU regulations mandating stricter sustainability practices and improved supply chain transparency.
“PACT has combined scientific rigor with design excellence to create a biomaterial platform that meets the highest standards of performance, sustainability, and scalability,” said Joy Faucher, Partner at Forbion BioEconomy. “We believe Oval has the potential to redefine how global brands source and use materials, offering a credible and commercially viable alternative to plastic-coated textiles and beyond. This Series A funding will enable PACT to scale production and meet rapidly growing demand, and we are excited to support the team as they bring their vision to market.”
“I’ve always been obsessed with creating new materials that are not only functional and kind to the planet, but also inherently beautiful — materials that feel gentle on the skin, supple, and pleasing to touch,” said Dr. Yudí Ding, co-founder and CEO of PACT. “As a Cambridge-trained scientist, developing them in the lab isn’t the hard part; the real challenge lies in scaling them to meet the exacting standards of the textile industry. From our very first investment, I realised that industrialisation and scalability are essential to making materials innovation truly succeed. That’s why we see existing manufacturers as key partners in this journey.”
With this Series A, PACT is poised to deliver commercial volumes of Oval to global partners and expand the portfolio via a newly commissioned state-of-the-art pilot line.
***ENDS***
For more information, please contact:
Forbion Investor Relations
Email: Robbert.van.de.Griendt@forbion.com
General Partner IR & Impact
Forbion Communications
Email: laura.asbjornsen@forbion.com
Head of Marketing & Communications
About PACT
PACT designs transformative, exquisite materials from resources the earth gifts us: collagen, herbal extracts, oils and minerals. PACT is determined to help humanity create products with efficiency and kindness — beginning with an advanced material made with a rich natural protein. PACT combines scientists and engineers, creatives and investors, all pioneering a material reality that benefits our biosphere. More information can be found on the website: https://pact.earth/
About Forbion
Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.
